EUCTR2007-002243-25-AT进行中（未招募）不适用
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 675
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •All patients randomized in the CAAE581A2203 core study
- •Patients who have signed a written informed consent before any trial procedure is performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have taken any anti-osteoporosis therapy since study participation (core or extension E1)
研究者
相似试验
进行中（未招募）
1 期
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-SKovartis Pharma Services AG675
进行中（未招募）
不适用
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisMedDRA version: 9.1Level: LLTClassification code 10031282Term: OsteoporosisOsteoporosisEUCTR2007-002243-25-FRovartis Pharma Services AG675
进行中（未招募）
不适用
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-PLovartis Pharma Services AG675
进行中（未招募）
不适用
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-CZovartis Pharma Services AG675
招募中
1 期
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone DeficiencyIdiopathic Growth Hormone DeficiencyCTIS2023-504020-25-00umos Pharma Inc.69